Welcome to our dedicated page for Amneal Pharmaceuticals SEC filings (Ticker: AMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Amneal Pharmaceuticals, Inc. filings document the regulatory record for a pharmaceutical issuer with Affordable Medicines, Specialty and AvKARE operations. The company’s 8-K reports cover operating and financial results, Regulation FD communications, clinical or regulatory disclosures, material agreements and capital-structure matters, including amendments to term loan credit arrangements involving Amneal Pharmaceuticals LLC and subsidiary guarantors.
Amneal’s proxy and annual-meeting filings describe board elections, advisory executive-compensation votes, auditor ratification and other stockholder voting matters. Its material-event disclosures also record governance matters, shareholder votes, opioids-related settlement obligations, and financial-statement exhibits tied to press releases and other public-company reporting.
Amneal Pharmaceuticals, Inc. is reported to have completed the acquisition of Kashiv BioSciences, LLC, with consideration that included both cash and stock. A reporting person, Chirag Patel, filed an amended beneficial ownership statement reflecting his updated holdings and the shares he received in connection with this transaction.
Under a Membership Interest Purchase Agreement, Amneal’s subsidiary agreed to pay the Kashiv sellers an aggregate of $375,000,000 in cash, subject to adjustments, and Amneal agreed to issue an aggregate of 28,942,098 shares of Class A Common Stock to those sellers. Chirag Patel is reported to beneficially own 29,097,645 shares of Class A Common Stock, representing 8.4% of the class, based on 377,238,115 shares outstanding after including the Kashiv-related issuance. His holdings include directly owned shares, stock options, and shares held through trusts and entities CKR Investments, LLC and Shivkan Dynasty, LLC, over which he is described as having sole voting and dispositive power.
Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, with its subsidiary Amneal Pharmaceuticals LLC purchasing 100% of Kashiv’s membership interests. As consideration at closing, Amneal LLC was required to pay the sellers an aggregate of $375,000,000 in cash, and Amneal was required to issue an aggregate of 28,942,098 shares of Class A Common Stock to the sellers, including CKR Dynasty, LLC and Shivkan Holdings, LLC, entities associated with Chintu Patel.
Following these transactions, Chintu Patel is reported as the beneficial owner of 32,576,528 shares of Amneal Class A Common Stock, representing 9.4% of the class, based on 348,296,017 shares outstanding plus the 28,942,098 shares issued in the Kashiv acquisition. The reporting person holds shares directly, through options, and through various trusts and entities over which he has control, with sole voting and dispositive power over all reported shares.
Amneal Pharmaceuticals, Inc. reported that Co-CEO and director Chintu Patel, through limited liability companies he manages, indirectly acquired 6,381,734 shares of Class A Common Stock on August 10, 2026. This equity was received as part of Amneal’s acquisition of Kashiv BioSciences, LLC, alongside cash consideration and other share issuances. Following this transaction, Patel also holds 1,388,521 shares directly and 24,753,252 shares indirectly through family trusts.
Amneal Pharmaceuticals, Inc. director Gautam Patel reported an indirect acquisition of 283,632 shares of Class A common stock on August 10, 2026. The shares were received by limited liability companies managed by him as part of Amneal’s acquisition of Kashiv BioSciences, LLC. Following this transaction, he also reported 1,643,963 shares held directly.
Amneal Pharmaceuticals, Inc. reported that President & Co-CEO Chirag K. Patel, through limited liability companies he manages, acquired 6,381,734 shares of Class A common stock on August 10, 2026. These shares were issued as part of Amneal’s acquisition of Kashiv BioSciences, LLC. After the transactions, Patel is reported as holding 1,393,470 shares directly and additional Class A shares indirectly, including 21,269,420 shares held by family trusts.
AMRX filed a notice of proposed resale of common stock under Rule 144. The planned sale involves 146,403 shares, all acquired as equity compensation on 03/01/2025, 03/03/2025, and 03/04/2025. The filing lists an approximate sale date of 08/12/2026 and indicates trading on NASDAQ.
Charles Schwab Corp filed a notice of proposed sale of 2,917,998 shares of its common stock under Rule 144. The filing lists prior equity compensation grants in the form of Restricted Stock Awards from 2017 through 2025, with individual grants ranging from a few thousand to over 76,000 shares. The issuer reports 319,353,919 common shares outstanding in connection with this planned resale.
Amneal Pharmaceuticals, Inc. completed the acquisition of Kashiv BioSciences, LLC, purchasing 100% of Kashiv’s membership interests through its wholly owned subsidiary Amneal Pharmaceuticals LLC. The consideration at closing included $375,000,000 in cash, subject to purchase price adjustments, and the issuance of 28,942,098 shares of Class A common stock as stock consideration to the sellers.
Under the purchase agreement, the sellers may receive up to an additional $350,000,000 in contingent payments tied to specified U.S. regulatory milestones for up to six Kashiv product candidates, plus potential contingent royalty payments over 12 years equal to 25% of certain annual gross profits above defined hurdles. To help fund the transaction, Amneal LLC entered into an amendment to its term loan credit agreement, under which Bank of America, N.A. provided a $350,000,000 incremental term loan.
Amneal amended its Stockholders Agreement to ensure the new stock consideration is counted in Amneal Group ownership calculations and relied on a private-offering exemption to issue the shares to accredited investors. The company plans to file an S-3 registration statement to permit public resale of the stock consideration and will later provide Kashiv’s financial statements and pro forma financial information.
Amneal Pharmaceuticals reported solid results for the three and six months ended June 30, 2026. Net revenue was $796,197 (in thousands) in Q2 2026 versus $724,508 (in thousands) a year earlier, and net income attributable to Amneal was $57,662 (in thousands) versus $22,417 (in thousands). For the first half, net revenue reached $1,518,716 (in thousands) and net income attributable to Amneal was $119,918 (in thousands). Diluted EPS was $0.18 in Q2 and $0.37 year-to-date. A very low effective tax rate of 1.9% in Q2 and 2.3% year-to-date supported bottom-line growth.
At June 30, 2026, Amneal held cash, cash equivalents and restricted cash of $139,619 (in thousands) and total assets of $3,776,348 (in thousands). Total debt was $2,684,263 (in thousands), primarily a Term Loan and Senior Notes due 2032, with interest expense, net of $108,404 (in thousands) for the first half. Operating cash flow swung to an outflow of $47,987 (in thousands), reflecting higher receivables, inventory builds and significant product-rights investments.
Strategically, Amneal is expanding through agreements including a $75,000 (in thousands) upfront payment to MSN for U.S. mirabegron rights, new tirzepatide and denosumab biosimilar arrangements, and a definitive deal to acquire Kashiv BioSciences for $375,000 (in thousands) in cash plus 28,942,108 shares and up to $350,000 (in thousands) in milestones and profit-based royalties. Legally, a Nationwide Opioids Settlement Agreement became effective, with total expected cash payments of $133.5 million through 2034 and naloxone product deliveries, and a $9,000 (in thousands) accrual was recorded for antitrust class action litigation.